Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Bloomer

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Cancer Chemotherapy and Pharmacology|October 3, 2002
Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamineM V Papadopoulou, M Ji, X Ji, et al.
The Mount Sinai Journal of Medicine, New York|March 1, 1988
Breast size, endogenous estrogens, and breast cancer: a review with hypothesisS Lehrer, E Levine, H K Song, et al.
Oncology Research|January 1, 1993
2-Alkylsulfonyloxy-3-hydroxy-1,4-naphthoquinones: a novel class of radio- and chemosensitizers of V79 cellsE Hatzigrigoriou, M V Papadopoulou, D Shields, et al.
The British Journal of Radiology|May 1, 1978
The complication probability factor: a method for selection of radiation treatment plansA Dritschilo, J T Chaffey, W D Bloomer, et al.
Cancer Letters|March 31, 1992
Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cellsJ A Prezioso, M W Epperly, N Wang, et al.
Biochemical Pharmacology|January 26, 1993
Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cellsJ A Prezioso, K M Damodaran, N Wang, et al.
Oncology Research|May 10, 2000
Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitroM V Papadopoulou, M Ji, S H Khan, et al.
Oncology Research|May 9, 2001
4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxinM V Papadopoulou, M Ji, M K Rao, et al.
Oncology Research|January 1, 1997
9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. IM V Papadopoulou, M Ji, M K Rao, et al.
Oncology Research|January 1, 1996
9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizerM V Papadopoulou, M Ji, M K Rao, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Cancer Chemotherapy and Pharmacology|October 3, 2002
Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamineM V Papadopoulou, M Ji, X Ji, et al.
The Mount Sinai Journal of Medicine, New York|March 1, 1988
Breast size, endogenous estrogens, and breast cancer: a review with hypothesisS Lehrer, E Levine, H K Song, et al.
Oncology Research|January 1, 1993
2-Alkylsulfonyloxy-3-hydroxy-1,4-naphthoquinones: a novel class of radio- and chemosensitizers of V79 cellsE Hatzigrigoriou, M V Papadopoulou, D Shields, et al.
The British Journal of Radiology|May 1, 1978
The complication probability factor: a method for selection of radiation treatment plansA Dritschilo, J T Chaffey, W D Bloomer, et al.
Cancer Letters|March 31, 1992
Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cellsJ A Prezioso, M W Epperly, N Wang, et al.
Biochemical Pharmacology|January 26, 1993
Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3-iodobenzene, a novel melanin precursor, in melanogenic melanoma cellsJ A Prezioso, K M Damodaran, N Wang, et al.
Oncology Research|May 10, 2000
Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitroM V Papadopoulou, M Ji, S H Khan, et al.
Oncology Research|May 9, 2001
4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxinM V Papadopoulou, M Ji, M K Rao, et al.
Oncology Research|January 1, 1997
9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. IM V Papadopoulou, M Ji, M K Rao, et al.
Oncology Research|January 1, 1996
9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizerM V Papadopoulou, M Ji, M K Rao, et al.
Pageof 11